lifesciencesreview
Optolane Technologies
Do Young Lee, CEO, Optolane Technologies
Do Young Lee, CEOA dramatically accelerating pace in the development of technological advancements in the field of genomics is enabling the sequencing of individual genomes in a relatively short time. However, genes are not homeostatic, which means constant and accumulated small mutations in cells can lead to genetic disorders or illnesses that gradually affect health. That has proven to be a major roadblock in the field of genetics and genomics. Mutations in the genome directly relate to external exposures and understanding such dynamic genome information is extremely difficult to consolidate. It requires full cooperation and support from the patient, who needs to provide precise information about one’s environment, lifestyle, and other non-genetic factors.

OPTOLANE Technologies, an innovator in the healthcare and diagnostics industry, has designed a platform that gives them direct contact with customers and helps them develop strategies for solutions. “Our diagnostic platform enables us to receive samples easily and perform genome sequencing as we concurrently create and correlate epigenetic situation data with customers to extract health check factors suitable for every situation,” says Do Young Lee, CEO. With the technology to develop diagnostic panels and the data to build more precise correlations, the company is designing a self-diagnosis system, as well as diagnostic items that can be used at home.

OPTOLANE enables diagnostic solutions to be built faster with its mutually viable platform, Lab On An Array (LOAA), where end customers can use various diagnostic services on one platform. Multiple categories of services include multiplex qualitative PCR, absolute quantitation of target genes, and multiplex quantitative and quantitation of protein markers. As a platform company, OPTOLANE enables any company or individual designing a diagnostic item to be a supplier for end customers on the LOAA platform.

Optolane Technologies: Spearheading Quantitative Gene Diagnosis

With the need for home-generated, regular biological data growing evident, OPTOLANE observed that daily, periodic measurements of various protein quantitative data could help achieve diagnosis faster, eliminating from data deviations of healthy homeostasis. In light of this prospect, Optolane introduces the concept of Imuno-PCR (a quantitative diagnostic technique that tags protein reactions with genes to find out the number of reactions) to develop a variety of protein diagnostic platforms, enabling precise quantitative diagnostic tests of large amounts of proteins at the picogram-femtogram level at home. And this is expected to have a great impact on disease prevention, which is the core of home healthcare.

While qualitative diagnostics is the current mainstay of genomic diagnosis, the ability to perform tests anywhere from a single platform will be the only way to meet increasing customer demand in the future. To this end, OPTOLANE’s addition of the absolute quantification method, Digital Real Time PCR, to its LOAA platform offers a wider diagnostic spectrum for customers. “The Digital Real Time PCR can perform much better and has improved usability over the Real Time qPCR,” says Lee.

The Digital Real Time PCR can perform much better and has improved usability over the Real Time qPCR

OPTOLANE uses the LOAA Digital PCR to offer quantitative diagnosis technology services for conventional blood cancer diagnosis and prognosis, with a 50 to 100 times higher quantitative limit than that of existing conventional genomics technologies. This will help quantify the degree of recurring treatments for leukemia patients and provide an important opportunity to improve the survival rate and prevent complications. OPTOLANE expects to offer high-quality services through the application of this technology and hopes to continue its efforts in liquid biopsy in the future.

As the future paradigm for diagnosis and medical services leans toward personalized medical services, the configuration of a diagnostic panel for individuals raises several practical issues, in terms of economic feasibility. To enable such personalization, OPTOLANE is planning a home diagnostic kit generator that can build a personalized diagnostic panel corresponding to information flowing into an individual’s home seamlessly.